AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05632289 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: osteopathic manipulative therapy
Description: osteopathic manipulative therapy : manuel therapy
Study NCT05632289 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham osteopathic manipulative therapy
Description: placebo of osteopathic treatment
Study NCT04887558 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Smart-T Mental Health and NRT
Description: Smart-Treatment Mental Health App and Nicotine Replacement Therapy
Study NCT04887558 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Smart-T Mental Health+ and NRT
Description: Smart-Treatment Mental Health App+NRT adherence messages and Nicotine Replacement Therapy
Study NCT04887558 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: QuitGuide + NRT
Description: NCI QuitGuide Treatment App and Nicotine Replacement Therapy
Study NCT06004336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given by vein (IV)
Study NCT06004336 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: Given by vein (IV)
Study NCT06117592 — intervention group
Intervention type: OTHER
Intervention: Education, training and assessment intervention
Description: Staff competence assessment documents for acute oncology knowledge and skills
Study NCT06187506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disitamab vedotin
Description: 2.0 mg/kg, administered intravenously every three weeks
Study NCT06187506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bacillus Calmette Guerin Vaccine
Description: Induction therapy, i.e., intravesical therapy once a week for 6 weeks. maintenance therapy, i.e., one course of maintenance therapy at three, six and twelve months after surgery, each course once a week for 3 weeks.
Study NCT05319847 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Daily Skin Supplement - Fountain of Youth
Description: Skincare supplement
Study NCT06210633 — intervention group
Intervention type: OTHER
Intervention: endovascular thrombectomy
Description: Endovascular thrombectomy with stent-retriever, local aspiration, angioplasty, and/or stenting.
Study NCT05425576 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OT-101
Description: OT-101 in combination of pembrolizumab
Study NCT04935736 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: root canal sealer : CORTISOMOL SP
Description: The participant will be treated with CORTISOMOL SP sealer in combination with gutta percha.
Study NCT04935736 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: root canal sealer : SEALITE REGULAR
Description: The participant will be treated with SEALITE REGULAR sealer in combination with gutta percha.
Study NCT04712175 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Nasopharyngeal sampling
Description: Swabs will be taken of nasopharyngeal samples for RT-PCR
Study NCT04712175 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Saliva sampling
Description: A 10ml saliva sample will collected in a sterile 60ml bottle for mass spectrometry and RT-PCR
Study NCT05055908 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed plus Pembrolizumab
Description: Atezolizumab(1200mg) ivgtt, every 21 days, or pembrolizumab, 200mg ivgtt, every 21 days etc. Pemetrexed, 500mg/m2, ivgtt, every 21 days
Study NCT05055908 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Atezolizumab(1200mg) ivgtt, every 21 days, or pembrolizumab, 200mg ivgtt, every 21 days etc.
Study NCT05055908 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed, 500mg/m2, ivgtt, every 21 days etc.
Study NCT05897424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INBRX-101
Description: A1PI, Recombinant, Bivalent Fc Fusion Protein
Study NCT06513468 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group education session by DESMOND Program
Description: is a validated structured education program for people with type 2 diabetes and their family members or carers (as appropriate)' This management approach was advised by the National Institute for Health and Care Excellence (NICE) in the UK since 2008. The program consists of a 6-hour face-to-face education session delivered by two trained educators over one day or two half-days to a group of 8-12 people with newly-diagnosed or ongoing type 2 diabetes. Annual reinforcement and review are part of the program , it is delivered as a business and usual in the secondary healthcare system of Qatar. The program is culturally adapted for Qatar considering beliefs and other health festivities.
Study NCT06513468 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group education session by DESMOND Program
Description: is a validated structured education program for people with type 2 diabetes and their family members or carers (as appropriate)' This management approach was advised by the National Institute for Health and Care Excellence (NICE) in the UK since 2008. The program consists of a 6-hour face-to-face education session delivered by two trained educators over one day or two half-days to a group of 8-12 people with newly-diagnosed or ongoing type 2 diabetes. Annual reinforcement and review are part of the program , it is delivered as a business and usual in the secondary healthcare system of Qatar. The program is culturally adapted for Qatar considering beliefs and other health festivities.
Study NCT05311969 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cognitive evaluations and non cognitive evaluations
Description: Cognitive evaluations with executive functions evaluations :~* Mini Mental State Examination~* Stroop Victoria Test~* Hayling test~* Frontal Assessment Battery test mental flexibility:~* Trial Making Test (TMT) A and B~* Connection test~* Alphaflex test~* Verbal and visuospatial working memory~* Wechsler Adult Intelligence Scale (WAIS) span~* Visuo-spatial span~* Visuo-spatial span simplified version~* Month Of the Year Backwards (MOTYB) Planning~* Tinker Toy test~* Clock Test~Non-cognitive evaluations:~The Katz Autonomy Scale Neuropsychiatric Inventory version Care team Geriatric Depression Scale 15-item version Apathy inventory
Study NCT04817982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perineural dexamethasone
Description: Dexamethasone 4mg will be added perineurally to an ulnar nerve block with bupivacaine.
Study NCT04817982 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Lidocaine 40 mg will be added perineurally to an ulnar nerve block with bupivacaine.
Study NCT04817982 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline will be added perineurally to an ulnar nerve block with bupivacaine.
Study NCT04817982 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Systemic dexamethasone
Description: Dexamethasone will be added perineurally to an ulnar nerve block with bupivacaine, some will be reabsorbed and distributed systemically. Thereby, the investigators control for the systemic effects of adding perineural dexamethasone to an ulnar nerve block.
Study NCT05877105 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ventilator-associated pneumonia prevention Evidence-based practices (VAPPEBP) which consists of ten items bundle
Description: VAP prevention EBP which consists of ten items bundle; hand hygiene, head-of-bed elevation, oral care with cetylpyridinium chloride, avoidance of oversedation, proper breathing circuit management, appropriate maintenance of endotracheal tube cuff pressure, closed system and subglottic suctioning, daily assessment for extubation, early ambulation and rehabilitation, and peptic ulcer and deep vein thrombosis (DVT) prophylaxis.
Study NCT05791331 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Surfactant administration following lung mechanics assessment in addition to clinical assessment
Description: Surfactant is administered following oxygenation-based criteria and if the Xrs is ≤ -23.3 cmH2O\*s /L
Study NCT05791331 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Surfactant administration following clinical assessment
Description: Surfactant is administered following oxygenation-based criteria
Study NCT05297838 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stationary Bike
Description: Stationary Bike while hand is submerged in ice bath
Study NCT05297838 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Virtual Reality (VR) Headset
Description: VR headset containing gameplay
Study NCT05297838 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ice Bath
Description: Pain was elicited via a cold pressor test, which is an established method of producing controlled and repeatable painful stimuli in an experimental setting
Study NCT06063343 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KAND145
Description: In Part 1 of the study, single ascending doses of KAND145 will be administered; in Part 2 of the study, multiple ascending doses (BID for 8 days) of KAND145 will be administered.
Study NCT06063343 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants randomized to the placebo arms will receive placebo at the same dosing frequency as the experimental arms.
Study NCT04490655 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active somatosensory training
Description: Patients in the experimental group will be required to move the robotic handle using their paretic arm from the start position to a visual target shown on screen. However, patients' paretic arm will be occluded from vision throughout the training session. They will make the reaching movement by depending on their proprioception of the arm position in space, without relying too much on the vision of their arm. Haptic guidance will be provided as somatosensory cues while participants are actively moving. Positive reinforcement will also be given for each successful movement that reaches the target in the form of a pleasant audio tone, visual feedback, and a running score. Assessment will be performed before and after the completion of the whole 15 training sessions.
Study NCT04490655 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motor-based training
Description: Patients in the control group will also be required to propel the robotic handle using their paretic arm to a target location. This training covers the same centre-out reaching movements but without any emphasis on proprioception, where the view of the paretic arm will not be occluded. However, no haptic guidance will be provided during the reaching movement. Positive reinforcement will still be given to inform the participants of their trial outcomes. Assessment will be performed before and after the completion of the whole 15 training sessions.
Study NCT05481281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: I/V bolus of dexmedetomidine 0.1 mg/kg as a 20 ml solution, followed by 0.04mg/kg/hr infusion
Study NCT05481281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: 0.2 mg/kg iv of ketamine diluted to 20 ml followed by 0.1 mg/kg/hr infusion
Study NCT05569941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABI-4334 Tablet
Description: ABI-4334 Tablet
Study NCT05569941 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ABI-4334 Placebo
Description: Placebo to ABI-4334 Tablet
Study NCT06195605 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Restylane-L
Description: Using a small gauge metal hub needle, two injections of CL-HA dermal filler (Restylane-L) will be performed, each into a small area (approximately 2 x 2 cm) of the mid-dermis of a forearm of a subject. Each injection will be 0.5 cc in volume, and will be approximately 2 cm apart from each other
Study NCT06195605 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vehicle
Description: Two injections of vehicle will be performed in the same manner as Restylane-L and in the same forearm, totaling 4 injections. A plastic template will be used to track the location of the injections, relative to landmarks on the skin.
Study NCT05484167 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Natesto Nasal Product
Description: Nasal Gel used for 90 days then crossed over to placebo gel
Study NCT05484167 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A nasal gel with no active ingredients
Study NCT05352113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSRIs
Description: SSRIs antidepressants will be used and the oral dose will be determined by the clinical specialist. Once-daily for 6 weeks.
Study NCT05352113 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: This study will use the intradermal needle as an acupuncture intervention. Acupoints related to MDD will be stimulated. According to the position of the acupoints, choose a needle of φ0.20\*1.5m or φ0.20\*1.2mm. Press the needle to insert the acupoint vertically and retain it in the skin. After the intervention, the needle will be retained for 72 hours with a day of rest after removal. During needle retention, participants will be instructed to press the acupoints 3-4 times a day for about 1 minute each time, with the amount of stimulation as much as the patient can tolerate, at an interval of about 4 hours. A total of 10 treatment sessions will be performed for 6 weeks.
Study NCT05352113 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sham acupuncture
Description: Sham acupuncture will use the same size, color, and material as the verum intradermal needle with a thin silicone pad in the middle instead of the needle body. The sham acupuncture will be needled on the points 1cm lateral to MDD-related acupoints. After the intervention, the needle will be retained for 72 hours with a day of rest after removal. A total of 10 sessions will be performed for 6 weeks.
Study NCT05352113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Oral placebo mimicking SSRIs antidepressants. Once-daily for 6 weeks.
Study NCT05276453 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GMove Suit
Description: 12 week, home-based programme whereby participants are encouraged to use the GMove suit daily, for at least 30 minutes a day. Recommended activities include walking, sit-to-stand and step-ups
Study NCT05276453 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Normal therapy
Description: Participants are randomized to a normal therapy (physiotherapy) only program. Participants are also advised to undertake 30 mins a day of physical activity and have active physical therapy (physiotherapy) sessions.
Study NCT06285903 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: internal sinus lift surgery
Description: surgery approach
Study NCT06016712 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SENSIMED Triggerfish Eye Lenses
Description: Contact lenses used for measuring intraocular pressure.
Study NCT06305065 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: KUNWU Navigation TKA procedure
Description: In terms of technical specifications, KUNWU is the only robotic arm with seven degrees of freedom, while other systems have a maximum of six. The ergonomic and user-friendly design of the system contributes to physical relief and simplified instrument handling, which enhances surgical precision and reduces cognitive stress.~KUNWU's navigation system boasts a refresh rate of 335Hz, which is significantly higher than the current 60Hz rate of other navigation systems. This high refresh rate provides a clear and visually captivating display of the navigation procedure, eliminating blurriness and indecipherable output. It enables surgeons to react promptly during live procedures, enhancing safety for both clinicians and patients and reducing potential complications and hospitalization.
Study NCT06305065 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CORI Surgical System TKA procedure
Description: The CORI Surgical System (Smith and Nephew®) represents one of such recent advances in robotics that it can assist surgical planning, and increase the accuracy of implant position due to real-time feedback during the procedure (bone resection, implant position, ligamentous balance).
Study NCT06305065 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional TKA procedure
Description: Total knee arthroplasty (TKA) is a highly successful and frequently performed surgical treatment to reduce disability caused by end-stage osteoarthritis and other conditions affecting articular cartilage. Technical outcomes for TKA are excellent, with favorable postoperative health-related quality of life. Also, survivorship of primary knee replacements is excellent with reported survivorship of 82.3% at 25 years. TKA has traditionally been indicated in the elderly population with relatively sedentary lifestyles, but more active, younger patients (\<55) are receiving TKA due to the desire for a pain-free, active lifestyle with the demand projected to continue to increase for this group. A recent systematic review has shown that functional outcomes are similar in this population compared to elderly patients with no increase in the burden of revision.
Study NCT05695430 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Cognitive Behavioral Therapy for People with Physical Disabilities
Description: 12 sessions of of Brief Cognitive Behavioral Therapy that has been adapted for people with physical disabilities will be administered through telehelath.
Study NCT05644509 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Oncolytic Virus Injection（Revottack）+PD-1
Description: Intravenous injection of Revottack injection combined with PD-1(Toripalimab） inhibitor
Study NCT06017466 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Visual Vertigo Analogue Scale (VVAS)
Description: The Visual Vertigo Analogue Scale (VVAS) was developed by E. Dannenbaum et al in 2011 to diagnose visual vertigo. It is a nine-item analogue scale in which the subjects can rated the intensity of their symptoms. The symptoms can be categorized as None (0), Mild (0.1-40), Moderate (40.01-70) or Severe (70.01-100). The VVAS is already available in English and French but a Dutch version does not yet exist.
Study NCT05255224 — intervention group
Intervention type: OTHER
Intervention: Not applicable as observational study
Description: Not applicable as observational study
Study NCT05673850 — intervention group
Intervention type: DRUG
Intervention: NET or NCT
Description: In this study, we included 518 ER-positive BC patients who received either neoadjuvant endo-crine therapy (NET) or neoadjuvant chemotherapy (NCT).
Study NCT04650945 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: isCGM group
Description: As previously described
Study NCT05367830 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: the Bone@BC app
Description: The bone@BC app is a diary for patients with breast cancer that they can use if they want to.
Study NCT05823454 — intervention group
Intervention type: DRUG
Intervention: Different drug dosage
Description: Choice of Anesthesia
Study NCT04902885 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trilaciclib, carboplatin, etoposide，or Topotecan
Description: Trilaciclib plus carboplatin, etoposide for first line patients ;Trilaciclib plus Topotecan for second or third line patients
Study NCT04902885 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo, carboplatin, etoposide，or Topotecan
Description: placebo plus carboplatin, etoposide for first line patients ;placebo plus Topotecan for second or third line patients
Study NCT06278259 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telerehabilitation program bases aerobic and Baduanjin exercises
Description: It is an interventional study in which 60 stroke patients estimated to enrol according to random allocation and divided into two groups. The study group participants involve in Telerehabilitation sessions is based on low-impact rhythmic movements, guided by video, according to the protocol of (Schachter et al., 2003). The telerehabilitation program is moderately intense aerobic exercise 3 times per week and included 3 parts: warm-up, central part, and cool-down. Each session : 30 min, 3 sessions/ week for 3 months.With the Baduanjin exercise program is delivered individually, at each patient's home, through telerehabilitation, with direct remote supervision by a physiotherapist
Study NCT06278259 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Telerehabilitation program bases aerobic exercises
Description: The telerehabilitation program is moderately intense aerobic exercise 3 times per week and included 3 parts: warm-up, central part, and cool-down. Each session : 30 min, 3 sessions/ week for 3 months.
Study NCT04360694 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Incremental hemodialysis
Description: 95 patients will start renal replacement therapy (RRT) with an incremental hemodialysis (once-weekly or twice-weekly) regimen.
Study NCT04360694 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional hemodialysis
Description: 95 patients will start renal replacement therapy (RRT) with the standard (thrice-weekly) hemodialysis regimen.
Study NCT05580692 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Biospecimen Sample Collection
Study NCT06547541 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: A body weight based resistance training.
Study NCT06561646 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: single-port robotic-assisted nipple-sparing mastectomy and sentinel lymph node biopsy
Description: the single-port robotic-assisted nipple-sparing mastectomy and sentinel lymph node biopsy in the management of breast cancer